Atossa Genetics Shares Move Higher Following News Co. to Demonstrate ForCYTE Test at Breast Cancer Symposium 2013
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM), will display its ForeCYTE Breast Health Test at the 7th annual Breast Cancer Symposium from September 7 through September 9, 2013 in San Francisco. Atossa's exhibit will be located in Booth 33 at the San Francisco Marriott Marquis -- Golden Gate Hall.
The ForeCYTE Breast Health Test, developed and marketed by Atossa's subsidiary, The National Reference Laboratory for Breast Health, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses Atossa's hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.